DDInter222 DDInter875
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Bortezomib {u} (Compound) resembles {v} (Compound) Aspartame
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A1
Bortezomib {u} (Compound) upregulates {v} (Gene) CASP7
Bortezomib {u} (Compound) is included by {v} (Pharmacologic Class) Proteasome Inhibitors
Bortezomib {u} (Compound) downregulates {v} (Gene) CNDP2
Bortezomib {u} (Compound) causes {v} (Side Effect) Urinary retention
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Bortezomib (Compound) resembles Aspartame (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Bortezomib (Compound) treats hematologic cancer (Disease)
Bortezomib (Compound) binds CYP1A1 (Gene)
Bortezomib (Compound) upregulates CASP7 (Gene)
Bortezomib (Compound) is included by Proteasome Inhibitors (Pharmacologic Class)
Bortezomib (Compound) downregulates CNDP2 (Gene)
Bortezomib (Compound) causes Urinary retention (Side Effect)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Alefacept